At present no definitive medical treatment exists for acute pancreatitis. [9,10] Pirenzepine has shown encouraging positive responses and a low incidence of adverse effects when used to treat ...
Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.
According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...
A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...
An early study with chimeric receptors between the alpha2c-adrenergic receptor and m3-muscarinic receptor suggested the possible heterodimerization between GPCR types. Direct evidence for GPCR ...
Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...
Emraclidine gave AbbVie entry into a group of companies developing drugs targeting muscarinic receptors, which are receptors in the central nervous system that play key roles in neuronal functions.
The M1/M4 muscarinic receptor agonist is vying to be the first drug to reach the market for schizophrenia with a new mechanism of action in decades. It is also in phase 3 clinical testing as an ...
Researchers discovered that xanomeline-trospium, a new-generation antipsychotic devoid of D2 dopamine receptor blocking ...